The Limited Times

Now you can see non-English news...

Novavax vaccination soon possible in Germany - these four vaccines could follow in 2022

2022-01-17T13:00:30.420Z


Novavax vaccination soon possible in Germany - these four vaccines could follow in 2022 Created: 01/17/2022, 13:50 The corona vaccine CoronaVac is currently being tested by the EMA. It could also be available in Germany soon. © Secretaria Salud Bogota/dpa From February you can protect yourself against Corona in Germany with a new vaccine. Four others are currently under review and may follow so


Novavax vaccination soon possible in Germany - these four vaccines could follow in 2022

Created: 01/17/2022, 13:50

The corona vaccine CoronaVac is currently being tested by the EMA.

It could also be available in Germany soon.

© Secretaria Salud Bogota/dpa

From February you can protect yourself against Corona in Germany with a new vaccine.

Four others are currently under review and may follow soon.

Munich - Biontech, Moderna and Johnson & Johnson - these vaccines are currently being vaccinated in Germany.

Now another one is added: Novavax.

And soon even more could follow.

Corona vaccinations with the preparation from the US manufacturer Novavax are expected to start in Germany at the end of February.

The first delivery of 1.75 million doses should be available from February 21, as Federal Minister of Health Karl Lauterbach said on Friday with reference to company information in Berlin.

Exact dates for a further 3.25 million cans that have been purchased have not yet been set.

He hopes for delivery in February.

Lauterbach explained that the preparation, which is "quasi an inactivated vaccine", should be particularly available to those who prefer this type of vaccination.

He himself could not assess the value of the Omicron variant well.

Four new vaccine candidates for Germany - two of them come from France

According to research by ZDF

, other vaccines could also

soon be available in Germany: Currently, “Vidprevtyn” by Sanofi Pasteur, “VLA2001” by Valneva, “Coronavac” by Sinovac and “Sputnik V” by the Gamaleja Institute have the best chance of being available. These are currently being examined by the EMA in a rolling review process. Vidprevtyn is a protein vaccine from France that is being developed jointly with the UK company GSK. Active protein ingredients can be kept for several months at normal refrigerator temperatures, and Germany has secured 20 million doses in the event of approval.

The second candidate is VLA2001, which is based on killed viruses.

Valneva is a Franco-Austrian company.

The company reported results from the phase 3 clinical trial that the compound was more effective than Astrazeneca and "well tolerated".

It should also keep at normal refrigerator temperature.

According to the Paul-Ehrlich Institute, VLA would be the first “whole virus vaccine” against Corona developed in the EU.

Eleven million doses were pre-ordered here.

Coronavac from China and Sputnik from Russia - soon also in Germany?

Coronavac, which also works with killed viruses, comes from China and is also a whole-virus vaccine.

It has been available in China since February 2021 and is also being vaccinated in other countries.

However, it is less effective than the vaccines commonly used in the EU.

Finally, the vector vaccine Sputnik V can hope for approval in Germany.

In August 2020 it was the first vaccine against Corona ever.

It is vaccinated in many states and

has also been declared safe and 90 percent effective by

The Lancet magazine.

However, the WHO did not recognize it due to a lack of data.

(cg)

The Omicron wave rolls over Europe.

Nevertheless, a German neighbor is now relaxing its strict Covid measures.

Many hosts protest that this does not apply to them.

Source: merkur

All news articles on 2022-01-17

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.